Overview
In clinical practice, Bladder Traininhg (BT) and Magnetic stimulation (MS) are frequently used together in the treatment of women with idiopathic overactive bladder (OAB). Up to our knowledge, there is no study evaluating the combined effect of magnetic stimulation and bladder training in women with idiopathic OAB in the literature. Moreover, there is no recommendation on conservative treament combinations in the guidelines due to insufficient data. At this stage, studies are needed to determine whether it will be effective to use MS in combination with other conservative treatment options. In addition, in the light of our clinical experience, we think that this issue is still open for research. In our study, adding MS to BT in women with idiopathic AAM is thought to contribute additionally to the efficacy of treatment with BT.
Our study is the first prospective randomized controlled trial that compares the efficacy of BT and BT plus MS in women with idiopathic OAB. In this study, we aimed to evaluate the efficacy of MS added to BT on incontinence-related QoL and clinical parameters in women with idiopathic OAB.
Description
This study is a prospectively randomized, controlled trial. The trial is held at Urogynecological Rehabilitation Unit of XXXX, Physical Medicine and Rehabilitation Department between September 2020 and November 2021. The local ethics committee approve the study (approvel no: 60116787-020/37878). Patients are informed about the purpose and contents of the study and all women give written consent to participate.
By using a random number generator, all patients which included the study were randomized into two groups as follows: The Group 1 received BT program alone, the Group 2 received BT plus MS.
Group 1: Bladder Training (BT) - Control group All women were informed about BT for 30 minutes. Then it was given as a written brochure to be implemented as a home program.
BT, consisting of four stages, did not contain any PFMT programs in two groups.
Group 2: BT plus MS Patients are told to sit on the chair with a magnetic coil below the chair. When a volume conductor is in serted by this magnetic eld, an eddy current ow is generated. This eddy current stimulates nerve or muscle of the pelvic oor. To apply MS, the device was set to generate its maximum stimuli, with a stimulation pulse width of 200 s and a stimulation repetition cycle of 10 Hz in accordance with the literature (10,13-15). When setting the device at each treatment session, patients were interviewed so that they received stimuli at the maximum stimulation intensity (maximum tolerable stimulation intensity) (10). MS was applied two days a week, 20 minutes a day, a total of 12 sessions for 6 weeks. MS sessions were performed by other physician.
Eligibility
Inclusion Criteria:
Women over the age of 18 with clinical diagnosis of idiopathic OAB Urodynamically conrmed detrusor overactivity (the presence of detrusor contractions in the lling phase of saline cystometry) Not tolerated or unresponsive to antimuscarinics and discontinued at least 4 weeks Able to give written, informed consent Able to understand the precedures, advantages and possible side effects Willing and able to complate the voiding diary and QoL questionnaire The strength of PFM 3/5 and more
Exclusion Criteria:
History of BT, MS therapy Pregnancy or intention to become pregnant during the study Current vulvovaginitis or urinary tract infections or malignancy More than stage 2 according to the pelvic organ prolapse quantification (POP-Q) Cardiac pacemaker, implanted defibrillator, coronary artery stent Ongoing treatment for arrhythmia Lower abdominal pain or dysmenorrhea yet to be diagnosed Electronic device or metallic implant applied to areas between the lumbar region and lower extremities Previous urogyneceological surgery within 3 months Ongoing surgical treatment or treatment with implantable devices for urinary incontinence or use of intrauterin copper devices Neurogenic bladder, signs of neurologic abnormalities at objective examination; history of the peripheral or central neurologic pathology Ultrasonographic evidence of PVR volume more than 100 ml